Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Analytical performance of the AtheNA MultiLyteŽ ANA II assay in sera from lupus patients with multiple positive ANAs.

Authors
Biagini-RE; Parks-CG; Smith-JP; Sammons-DL; Robertson-SA
Source
Anal Bioanal Chem 2007 Jun; 388(3):613-618
NIOSHTIC No.
20032021
Abstract
The purpose of this study was to evaluate the precision and accuracy of a commercial multiplexed kit for the measurement of 9 anti-nuclear antibodies (ANAs; anti-SS/A, anti-SS/B, anti-Sm, anti-RNP, anti-Jo-1, anti-Scl-70, anti-dsDNA, anti-Centromere B, and anti-Histone), and to compare these results to a subset of ANAs measured by enzyme-linked immunosorbent assays (ELISA) and immunodiffusion (ID). Sera were obtained from 22 systemic lupus erythematosus (SLE) patients, twelve controls and five others (commercial source) with various autoimmune diseases. ANA results from the AtheNA MultiLyteŽ ANA II Assay (AtheNA) were compared to ELISA results (controls) and patients (ID). The AtheNA interassay coefficients of variation (CVs, N = 39, performed in duplicate; replicated 3×) ranged from 6.2% to 16.7% (mean = 9.8%), while the intra-assay CVs ranged from 5.8% to 14.3% (mean = 10.8%). Compared to results for SLE cases and controls, the sensitivity of AtheNA ranged from 85.7% to 100% (mean = 97.1%), while diagnostic specificity ranged from 16.7% to 100% (mean = 71.6%). There was significant agreement (P values ranging from 0.0001 to 0.03) when analytes coanalyzed by AtheNA and ELISA/ID were evaluated using Cohen's kappa (? values ranging from 0.376 to 1.000). No false positive ANA results were observed for either the control or commercial source autoimmune disease sera. These results indicate that the AtheNA assay is a precise and accurate alternative for performing multiple ELISAs or IDs in the diagnosis of autoimmune diseases, especially when the number of sera to be tested is large, such as in clinical screening or epidemiologic studies. It also appears that the AtheNA assay identifies positive ANA specificities which are missed by ID techniques, suggesting that it may have greater analytical sensitivity for some ANAs.
Keywords
Exposure-levels; Toxic-effects; Nuclear-medicine; Epidemiology; Clinical-tests; Analytical-methods; Analytical-processes; Analytical-Method; Immune-reaction; Immune-system-disorders; Immunologic-disorders; Immune-system; Cancer
Contact
Biological Monitoring Research Team, Biomonitoring and Health Assessment Branch, DART, National Institute for Occupational Safety and Health (NIOSH), CDC, MS C26, Robert A. Taft Laboratories, 4676 Columbia Parkway, Cincinnati, OH 45226
CODEN
ABCNBP
Publication Date
20070601
Document Type
Journal Article
Email Address
rbiagini@cdc.gov
Fiscal Year
2007
NTIS Accession No.
NTIS Price
Issue of Publication
3
ISSN
1618-2642
NIOSH Division
DART
Source Name
Analytical and Bioanalytical Chemistry
State
OH; WV
TOP